Evidence map›Paper›PMID 42754915›Full record

SynthesisCancer reports (Hoboken, N.J.)2026

Cardiovascular Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Case Reports.

Shea-Lee Godin, Tyler Kingma, Ashwin Pillai, Obada Kholoki, Agnes S Kim

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shea-Lee GodinDepartment of Medicine, University of Connecticut Health, Farmington, Connecticut, USA.ORCID https://orcid.org/0000-0003-3227-368X
Tyler KingmaDepartment of Medicine, University of Connecticut Health, Farmington, Connecticut, USA.
Ashwin PillaiDepartment of Medicine, University of Connecticut Health, Farmington, Connecticut, USA.ORCID https://orcid.org/0000-0003-0543-2235
Obada KholokiDepartment of Medicine, University of Connecticut Health, Farmington, Connecticut, USA.ORCID https://orcid.org/0000-0002-3835-7676
Agnes S KimDepartment of Medicine, Division of Cardiology, University of Connecticut Health, Farmington, Connecticut, USA.ORCID https://orcid.org/0000-0002-7487-9340

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReports of immune checkpoint inhibitor (ICI) therapy-associated immune-related adverse events (irAEs) exhibit considerable heterogeneity, particularly when comparing data from clinical trials and real-world observational studies.

methodsWe conducted a systematic review of real-world observational studies (case reports and series) reporting cardiovascular irAEs in PubMed and Embase from inception to April 1, 2024. We analyzed 116 case reports from 115 studies and highlighted the commonest irAEs, treatments instituted, and ensuing outcomes.

resultsMyocarditis was the most common, accompanied frequently by pericarditis and heart failure. Treatment typically included corticosteroids and discontinuation of ICI therapy. Higher doses of corticosteroids appeared promising. Refractory cases benefited from plasmapheresis, intravenous immunoglobulin, mycophenolate, tacrolimus, or infliximab. Rechallenging ICI therapy after irAEs resulted in mixed outcomes.

conclusionsGiven the heterogeneity of data, analysis of aggregated data from central repositories like Side Effect Registry Immuno-Oncology (SERIO) would be invaluable.

Indexed as

Heart FailureImmune Checkpoint InhibitorsMyocarditisNeoplasmsPericarditisCase Reports as TopicHumansImmune Checkpoint Inhibitors

Identifiers

PMID42754915
PMCPMC13585987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.